Wall Street analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to post earnings of $5.61 per share for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Regeneron Pharmaceuticals’ earnings. The highest EPS estimate is $6.28 and the lowest is $4.60. Regeneron Pharmaceuticals posted earnings per share of $5.23 in the same quarter last year, which would indicate a positive year-over-year growth rate of 7.3%. The company is scheduled to announce its next quarterly earnings results on Thursday, February 14th.
On average, analysts expect that Regeneron Pharmaceuticals will report full year earnings of $21.49 per share for the current year, with EPS estimates ranging from $20.08 to $22.29. For the next fiscal year, analysts anticipate that the business will report earnings of $22.51 per share, with EPS estimates ranging from $19.08 to $26.69. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that cover Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported $5.87 EPS for the quarter, topping analysts’ consensus estimates of $4.94 by $0.93. The firm had revenue of $1.66 billion for the quarter, compared to the consensus estimate of $1.64 billion. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The firm’s revenue was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.99 earnings per share.
REGN stock traded down $8.86 during trading on Friday, reaching $372.83. 835,844 shares of the company were exchanged, compared to its average volume of 626,753. The company has a market cap of $41.30 billion, a P/E ratio of 27.80, a P/E/G ratio of 1.63 and a beta of 1.36. Regeneron Pharmaceuticals has a 52-week low of $281.89 and a 52-week high of $416.49. The company has a current ratio of 4.04, a quick ratio of 3.30 and a debt-to-equity ratio of 0.09.
In related news, Director Michael S. Brown sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, September 27th. The shares were sold at an average price of $392.26, for a total transaction of $784,520.00. Following the transaction, the director now owns 2,000 shares of the company’s stock, valued at $784,520. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 12.42% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Rehmann Capital Advisory Group lifted its stake in shares of Regeneron Pharmaceuticals by 1,700.0% during the third quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 68 shares during the period. Icon Wealth Partners LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $112,000. Signaturefd LLC lifted its stake in shares of Regeneron Pharmaceuticals by 123.8% during the second quarter. Signaturefd LLC now owns 358 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 198 shares during the period. Flagship Harbor Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $159,000. Finally, Columbia Asset Management purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $196,000. 67.24% of the stock is currently owned by institutional investors and hedge funds.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Further Reading: How Do You Calculate Return on Equity (ROE)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.